What a ClinicalTrials.gov record can establish

Question

What can a public ClinicalTrials.gov registry record support as evidence, and what can it not support?

Who can use this

• Research, data and evidence teams deciding how to label registry-derived fields in an evidence record.
• Architects designing source models that keep registration, results posting and FDA review as separate facts.
• Editors and analysts checking whether a written statement about a registered study goes beyond what the record supports.

Chronology

1. 2000 The Federal Register notice describes ClinicalTrials.gov as a registry and results data bank operated by NLM, NIH, since 2000.
2. 2007-09-27 The Food and Drug Administration Amendments Act of 2007 was enacted, with Title VIII, Section 801 titled expanded clinical trial registry data bank.
3. 2016-09-21 The final rule on registration and results information submission was published in the Federal Register.
4. 2017-01-18 The final rule took effect, and the NIH dissemination policy applied to competing applications and contract proposals submitted on or after this date.
5. June 2023 NLM's handout states that the ClinicalTrials.gov website was modernized.
6. 2026-11-02 Registry counts used in this brief were retrieved through the public API, which reported a data timestamp of 2026-11-02T10:00:05.

Claims

Observed

C-01 NLM states that a listing on ClinicalTrials.gov does not mean the federal government evaluated the study. National Library of Medicine, National Institutes of Health
Source text: “Listing a study does not mean it has been evaluated by the U.S. Federal Government.”

C-02 NLM states that registry information comes from the study's sponsor or investigator. National Library of Medicine, National Institutes of Health
Source text: “provided by the sponsor or investigator of the study”

C-03 The final rule's preamble states that the government does not independently verify the scientific validity or relevance of submissions. National Institutes of Health, Federal Register
Source text: “the government does not independently verify the scientific validity or relevance of the information submitted”

C-04 The preamble describes NIH quality control review as directed at clarity and completeness, and not at the quality or validity of the trial. National Institutes of Health, Federal Register
Source text: “focused on the clarity and completeness of the information submitted, not the quality, validity, meaning or relevance of the trial itself”

C-05 The preamble states that inclusion in the registry and the limited review are not a government affirmation or verification of the information. National Institutes of Health, Federal Register
Source text: “do not constitute a government affirmation or verification that the information within or referenced in the database”

C-06 The preamble states that required information can be posted before quality control review has finished, because review does not change the posting deadlines. National Institutes of Health, Federal Register
Source text: “posted even though the quality control review process has not concluded”

C-07 The preamble ties assignment of an NCT number to the conclusion of quality control review. National Institutes of Health, Federal Register
Source text: “will not assign an NCT number until the quality control review process has concluded”

C-08 The regulation's definition of an applicable drug clinical trial excludes phase 1 clinical investigations. Department of Health and Human Services, published by the Government Publishing Office
Source text: “a controlled clinical investigation, other than a phase 1 clinical investigation”

C-09 The regulation's results requirement applies to specified applicable clinical trials and is subject to waiver. Department of Health and Human Services, published by the Government Publishing Office
Source text: “Unless a waiver of the requirement to submit clinical trial results information is granted”

C-10 The regulation places a truthfulness duty on the responsible party who submits the information. Department of Health and Human Services, published by the Government Publishing Office
Source text: “submitted by a responsible party under this part shall not be false or misleading in any particular”

C-11 The regulation provides for voluntary submission for some trials outside the mandatory requirements. Department of Health and Human Services, published by the Government Publishing Office
Source text: “voluntarily submits clinical trial registration information and/or clinical trial results information”

C-12 FDA describes its marketing review as a separate process in which a review team examines submitted data and reaches a decision. U.S. Food and Drug Administration
Source text: “The FDA review team thoroughly examines all submitted data on the drug and makes a decision to approve or not to approve it.”

C-13 FDA describes a distinct review of the original investigational new drug submission before clinical research on a drug begins. U.S. Food and Drug Administration
Source text: “The FDA review team has 30 days to review the original IND submission.”

C-14 FDA's description of phase 2 states that studies of that size are not large enough to show benefit, so a phase label alone is not a finding of benefit. U.S. Food and Drug Administration
Source text: “these studies aren't large enough to show whether the drug will be beneficial”

C-15 WHO characterizes trial registration as publishing an agreed set of information about a trial. World Health Organization
Source text: “WHO regards trial registration as the publication of an”

C-16 NIH sets an expectation for funded trials to register and submit results that is framed as a funder policy alongside the federal regulation. National Institutes of Health, Office of Extramural Research
Source text: “All NIH-funded clinical trials are expected to register and submit results information to”

C-17 A neighboring FDA data source carries a parallel limit: the existence of an adverse event report does not establish that a product caused the event. U.S. Food and Drug Administration
Source text: “Existence of a report does not establish causation”

Derived

C-18 On 2026-11-02, 80,822 of 609,811 registry records, about 13.3 percent, carried posted results. National Library of Medicine, National Institutes of Health
Basis: Counts returned by the public API at /api/v2/studies with countTotal=true, with no filter for the total and with filter.advanced=AREA[HasResults]true for the numerator; 80,822 divided by 609,811.

C-19 On 2026-11-02, 67,428 of 333,659 records with an overall status of completed, about 20.2 percent, carried posted results, so about 79.8 percent of completed records showed none in the registry. National Library of Medicine, National Institutes of Health
Basis: Counts returned by the public API using filter.advanced=AREA[OverallStatus]COMPLETED, with and without AND AREA[HasResults]true; 67,428 divided by 333,659.

C-20 On 2026-11-02, 465,324 of 609,811 records, about 76.3 percent, were interventional, so a registry record is not necessarily a record of an interventional trial. National Library of Medicine, National Institutes of Health
Basis: Counts returned by the public API using filter.advanced=AREA[StudyType]INTERVENTIONAL; 465,324 divided by 609,811.

Inferred

C-21 The fact of registration supports the statement that information about a study was submitted and posted, and does not support a statement that the study was reviewed for scientific merit or evaluated by the government. National Library of Medicine, National Institutes of Health, National Institutes of Health, Federal Register
Basis: Follows from C-01, C-02, C-03 and C-05, which attribute the content to submitters and disclaim government verification.

C-22 A missing results section cannot by itself show either that no results exist or that a requirement was breached. Department of Health and Human Services, published by the Government Publishing Office, National Library of Medicine, National Institutes of Health, National Center for Biotechnology Information, National Library of Medicine
Basis: Follows from C-08, C-09 and C-11, because the requirement varies with trial type and waiver status and some submissions are voluntary, and from C-19, which measures only what the registry displays; results may also appear in literature indexed elsewhere, as SRC-12 describes.

C-23 An NCT number indicates that quality control review of a registration concluded, and it does not indicate that the study's quality or validity was assessed. National Institutes of Health, Federal Register
Basis: Follows from C-07, which ties the number to the review, read with C-04, which limits the review to clarity and completeness.

C-24 Record fields such as isFdaRegulatedDrug describe a study attribute and cannot be read as evidence that FDA evaluated the study or its results. National Library of Medicine, National Institutes of Health, National Library of Medicine, National Institutes of Health, U.S. Food and Drug Administration
Basis: The field appears in the oversight schema of SRC-02 as a boolean; C-02 attributes record content to sponsors and investigators, and C-12 places FDA's decision in a separate review process.